Amphastar Pharmaceuticals financials
$26.68−2.59%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $719.9M | $732.0M | $644.4M | $499.0M | $437.8M | $349.8M | $322.4M | $294.7M | $240.2M | $255.2M |
| Gross profit | $356.1M | $373.9M | $351.1M | $248.9M | $199.7M | $143.3M | $131.9M | $107.0M | $90.5M | $104.2M |
| Gross margin | 49.5% | 51.1% | 54.5% | 49.9% | 45.6% | 41.0% | 40.9% | 36.3% | 37.7% | 40.8% |
| Operating income | $140.4M | $205.4M | $197.0M | $107.5M | $69.9M | $11.0M | -$39.0K | -$8.6M | -$3.9M | $15.4M |
| Net income | $98.1M | $159.5M | $137.5M | $91.4M | $62.1M | $1.4M | $48.9M | -$5.7M | $3.6M | $9.8M |
| Net margin | 13.6% | 21.8% | 21.3% | 18.3% | 14.2% | 0.4% | 15.2% | −1.9% | 1.5% | 3.8% |
| Diluted EPS | $2.03 | $3.06 | $2.60 | $1.74 | $1.25 | $0.03 | $0.98 | $-0.12 | $0.08 | $0.21 |
| EBITDA | $197.1M | $258.4M | $235.0M | $132.3M | $96.4M | $36.1M | $21.1M | $7.9M | $11.9M | $30.1M |
| Operating cash flow | $156.1M | $213.4M | $183.5M | $89.2M | $98.0M | $57.3M | $41.8M | $38.2M | $39.2M | $38.6M |
| Free cash flow | $121.2M | $172.3M | $145.3M | $65.1M | $70.5M | $23.4M | $207.0K | -$8.6M | $4.1M | $17.2M |
| Diluted shares | 48.2M | 52.1M | 53.0M | 52.4M | 49.8M | 49.1M | 49.9M | 46.4M | 48.4M | 47.5M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $170.2M | $151.6M | $144.3M | $156.1M | $126.4M | $92.6M |
| Short-term investments | $112.6M | $70.0M | $112.5M | $19.7M | $10.3M | $13.0M |
| Total debt | $610.4M | $601.9M | $590.0M | $75.9M | $77.0M | $46.4M |
| Total assets | $1.63B | $1.58B | $1.51B | $742.0M | $671.5M | $631.2M |
| Total liabilities | $840.5M | $845.2M | $873.5M | $213.3M | $226.0M | $182.5M |
| Shareholders' equity | $788.8M | $732.3M | $639.4M | $528.7M | $445.5M | $448.7M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology